---
title: "Asthma and dupilumab therapy"
subtitle: "PSPG219"
width: 1920
height: 1080
margin: 0
padding: 0
max-scale: 1.5
format:
    revealjs:
        chalkboard:
            buttons: false
        preview-links: auto
        logo: public/ucsf.png
        theme: simple
        css: css/styles.css
---

## Asthma is one of the most common non-communicable diseases worldwide

::: columns
::: {.column width="30%"}  
<br> 
<h3> High costs, high disparity </h3>
* 2008-2013: $81.9 billion in costs (US) from asthma
* for children, top cause of missed school days 
* some variability in estimates due to disease heterogeneity
* disparities by sex, socioeconomic status, race/ethnicity
:::

::: {.column width="2%"}
:::

::: {.column width="68%"}
::: {.r-stack}
![](public/asthmasymptoms.jpg){.fragment .fade-in-then-out style="height: auto; width: 150%; max-width: 1050%; display: block"}

![](public/asthmaglobal.jpg){.fragment .fade-in-then-out style="height: auto; width: 105%; max-width: 1050%"}

![](public/disparities.png){.fragment style="height: auto; width: 100%; max-width: 100%"}
:::
:::

:::

## Historically, small molecules have been standard of care

:::  columns
::: {.column width="50%"}

::: {.fragment fragment-index="1"}
<br> <br>
<p> Albuterol (salbutamol) </p>
-   $\beta_{2}$ adrenergic receptor agonist
-   causes dilation of bronchioles, vasodilation
-   long acting and short acting variants, some controversy over usage and efficacy 

:::

::: {.fragment fragment-index="2"}

<br> <br> 
<p> Inhaled corticosteroids </p>
-   steroids help reduce inflammation 
-   some overlap with drugs meant to treat eczema, dermatitis etc
:::

:::

::: {.column width="50%"}

<img src="public/salbutamol.png" class="fragment" data-fragment-index="1" style="height: auto; width: 80%">

<img src="public/qvar.png" class="fragment" data-fragment-index="2" style="height: auto; width: 80%">

:::
:::

## Antibody therapy has potential to be more specific, effective

What is the target of dupilumab? <span class="fragment fade-in" data-fragment-index="1" style="font-weight: bold; color: red"> the IL-4R$\alpha$ (IL4-receptor, $\alpha$ subunit) </span>

::: columns
::: {.column}

<img src="public/il4.png" class="fragment" data-fragment-index="2">

:::

::: {.column}

<br>
<br>

::: {.fragment fragment-index="2"}
-   receptor binds IL-4 and IL-13 $\rightarrow$ activates iGE production
-   iGE $\rightarrow$ mast cell histamine release $\rightarrow$ B-cell, CD-4+ T-cells, eosinophils recruited

:::

::: {.fragment fragment-index="2"}
-   IL-4 and IL-13 also signals airway smooth muscle cells and epithelial cells
:::

:::
:::

## Dupilumab mechanism of action

<img src="public/dupilumab-moa-edit.png">

## 
<h2> How was dupilumab discovered? </h2>
<h3> VelocImmune platform for humanized antibody discovery </h3>

<div class="r-stack">
<div class="fragment fade-in-then-out">
<img src="public/velocimmune.png" style="height: auto; width: 65%; display: block; margin-left: auto; margin-right: auto">
<br>
VelocImmune mice have human VDJ regions, but mouse constant and regulatory regions 
</div>

::: {.fragment}
::: columns
::: {.column}
<img src="public/abgen.png" style="height: auto; width: 50%; max-width: 50%; position: relative; left: 20rem; top: -1.5rem">
:::

::: {.column}  
<br>
<br>


* antibodies generated from mice are sometimes immunogenic 


* VelocImmune generates antibodies that are significantly less immunogenic, greatly reducing development time
* Mice were injected with IL-4R$\alpha$ receptor protein
:::

:::
:::
</div>

## Efficacy & safety [52 week, 1902 patient study]

::: {.r-stack}
<img src="public/fevdelta.png" class="fragment fade-in-then-out" data-fragment-index="1" style="width: auto; height: 100%">
<span class="fragment fade-in-then-out" data-fragment-index="1" style="text-align:center; display: block"> <br>  FEV measures total lung volume exhaled in first second of exhalation test </span>

<br>
<br>
<img src="public/relative-risk.png" class="fragment fade-in-then-out" data-fragment-index="2" style="width: 100%; height: auto; max-width: 100%; display: block; transform: scale(1.5, 1.5)">
<span class="fragment fade-in-then-out" data-fragment-index="2"> <br> <br> Rate of severe asthma exacerbations was ~ half from placebo </span>

<img src="public/efficacy-edited.png" class="fragment" data-fragment-index="3" style="transform: scale(1.2,1.2); position: relative; top: 5rem">
:::


::: {.footer}
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma, Castro et al., NEJM 2018
::: 


## Questions?

<br>
<br>
<br>
<img src="public/mouse.png" style="display: block; margin-left: auto; margin-right: auto; transform: scale(1.4, 1.4)">
